Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer

2015/08/11 by Carol Aghajanian, Barbara A. Goff, Barbara Goff +4 · 1 citation
Medicine · #Ovarian cancer diagnosis and treatment #PARP inhibition in cancer therapy #Ferroptosis and cancer prognosis

paper · doi:10.1016/j.ygyno.2015.08.004

Cited by

• A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission: An NRG Oncology/GOG study